Results 61 to 70 of about 4,643,128 (344)

Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.

Pharmacology and Therapeutics, 2020
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause characterized by relentless scarring of the lung parenchyma leading to reduced quality of life and earlier mortality.
P. Spagnolo, J. Kropski, Mark G. Jones, Joyce S. Lee, G. Rossi, T. Karampitsakos, T. Maher, A. Tzouvelekis, C. Ryerson   +8 more
semanticscholar   +1 more source

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

The Journal of Headache and Pain, 2021
Background Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple factors, including general efficacy,
F. Vandervorst, L. Van Deun, A. Van Dycke, K. Paemeleire, U. Reuter, J. Schoenen, J. Versijpt   +6 more
semanticscholar   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy

Epilepsia Open, 2019
Objective To study the effectiveness and tolerability of antiepileptic drugs (AEDs) commonly used in juvenile myoclonic epilepsy (JME). Methods People with JME were identified from a large database of individuals with epilepsy, which includes detailed ...
Katri Silvennoinen, Nikola deLange, Sara Zagaglia, Simona Balestrini, Ganna Androsova, Merel Wassenaar, Pauls Auce, Andreja Avbersek, Felicitas Becker, Bianca Berghuis, Ellen Campbell, Antonietta Coppola, Ben Francis, Stefan Wolking, Gianpiero L. Cavalleri, John Craig, Norman Delanty, Michael R. Johnson, Bobby P. C. Koeleman, Wolfram S. Kunz, Holger Lerche, Anthony G. Marson, Terence J. O’Brien, Josemir W. Sander, Graeme J. Sills, Pasquale Striano, Federico Zara, Job van derPalen, Roland Krause, Chantal Depondt, Sanjay M. Sisodiya, the EpiPGX Consortium   +31 more
doaj   +1 more source

Evidence of superiority of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers in the heart failure with reduced ejection fraction patient's journey

Cardiology Plus, 2021
Sacubitril/valsartan (S/V) is a new drug which has been recently recommended by the international guidelines for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF).
Mauro Gori, Emilia D'Elia, Michele Senni
doaj   +1 more source

Selective review and commentary on emerging pharmacotherapies for opioid addiction. [PDF]

, 2011
Pharmacotherapies for opioid addiction under active development in the US include lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode of delivering buprenorphine for six months, thus relieving patients, clinicians,
Ling, Walter, Miotto, Karen, Mooney, Larissa, Nielsen, Suzanne, Torrington, Matthew, Zhao, Min   +5 more
core   +2 more sources

Methadone tolerance testing in drug misusers [PDF]

BMJ, 2006
Asking drug misusers the dose they need for methadone maintenance might seem like an invitation to exaggerate, but experience in one practice suggests that it could improve uptake of treatment without compromising ...
Adam, Bakker, Cindy, Fazey
openaire   +2 more sources

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis

Lancet psychiatry, 2018
Summary Background The benefits and safety of medications for attention-deficit hyperactivity disorder (ADHD) remain controversial, and guidelines are inconsistent on which medications are preferred across different age groups.
S. Cortese, N. Adamo, C. Del Giovane, Christina Mohr-Jensen, A. Hayes, S. Carucci, L. Atkinson, Luca Tessari, T. Banaschewski, D. Coghill, C. Hollis, E. Simonoff, A. Zuddas, C. Barbui, M. Purgato, H. Steinhausen, F. Shokraneh, Jun Xia, A. Cipriani   +18 more
semanticscholar   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Korean Medication Algorithm Project for Bipolar Disorder 2022: Treatment Strategy According to Safety and Tolerability

European Psychiatry
Introduction Accordingly, the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) working committee, composed of domestic experts, developed Korea’s first KMAP-BP in 2002 and later in 2006, 2010, and 2010. A revised version of KMAP-BP was
S. Y. Park, W.-M. Bahk, Y. S. Woo, D.-I. Jon, M.-D. Kim, I. Sohn   +5 more
doaj   +1 more source